Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$5.37 USD
-0.02 (-0.37%)
Updated Apr 26, 2024 09:37 AM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
TVTX 5.37 -0.02(-0.37%)
Will TVTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TVTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TVTX
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
TVTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a Bet
Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli
Other News for TVTX
Travere Therapeutics (TVTX) Receives a Hold from Piper Sandler
Buy Rating Affirmed for Travere Therapeutics Following Filspari’s European Approval and Promising US Prospects
Buy Rating Affirmed for Travere Therapeutics on EU Approval and Promising Revenue Projections
Analysts Conflicted on These Healthcare Names: Travere Therapeutics (TVTX), Humana (HUM) and Merck & Company (MRK)
FILSPARI’s European Approval and Market Potential Bolster Buy Rating for Travere Therapeutics